Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Video

Where can patients go to get CAR-T cell therapy?

Posted by
HealthTree Logo HealthTree
• September 10, 2022

Description

Find out where patients can go to receive CAR-T cell therapy in this video.

On this video

Transcript

Where can people go to get CAR T cell therapy? So these CAR T products, all of them, not just in myeloma, are available through authorized treatment centers. And the best way to know who is an authorized treatment center is to go on the company website and look up authorized treatment centers for that specific product. I know that in many hospitals this is still undergoing an onboarding process. Unlike regular drugs that we can simply buy from the pharmacy, CAR T products require certain training management algorithms and contracting directly with the hospital that administers them. So there's a process that a hospital needs to undergo to onboard a CAR T product. There is some degree of expertise that's required in administering CAR T cells and we have a lot of experience in treating lymphoma and leukemia patients. We're using that experience so we can treat the myeloma patients better as well. So to mitigate some of the side effects and to manage some of these patients, the best thing to do is to go to an authorized treatment center that has a lot of experience in treating CAR T cell patients, even if it's in other diseases. Does insurance cover CAR T cell therapy? That's an excellent question, which is challenging to answer in a global way. We have had quite good success in obtaining insurance approval in CAR T cells and lymphoma. We have in fact not seen a huge number of barriers in getting those CAR T cells to the patients who need them. There are still things that need to be resolved in terms of the financial aspects of CAR T cell therapy, but we have seen fairly good reception by insurance companies with the understanding that these are highly effective therapies and they're more effective than anything else you could administer to this type of patients who have been refractory to other therapies. So the insurance companies understand that and I believe that's the reason why we have not seen dramatic barriers in this area.

Related Content